Trial Profile
A Phase I/II, Open-Label, Single Center Study to Evaluate the Tolerability, Trafficking and Therapeutic Effects of Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV Infected Subjects.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lexgenleucel T (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2019 Status changed from active, no longer recruiting to completed.
- 04 Aug 2011 Planned end date changed from 1 Sep 2009 to 1 Dec 2020 as reported by ClinicalTrials.gov.
- 11 Aug 2009 Planned end date changed from 1 Jul 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.